January 13, 2025 06:58 AM EST

Gilead taps into STAT6 space via $250M deal with Leo Pharma

Ayisha Sharma

News Reporter

Gilead has inked a deal to license Leo Pharma’s portfolio of oral STAT6 candidates for inflammatory diseases, less than a month after Johnson & Johnson …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead taps into STAT6 space via $250M deal with Leo Pharma

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

J&J to buy Intra-Cellular for $14.6B in latest neuroscience bet

GSK kicks off JPM dealmaking with $1B+ buyout of IDRx and its rare cancer drug

#JPM25 live blog: How important are this morning’s deals to a biotech recovery? Insiders weigh in

Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo

Bayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to Phase 3 trial

Biogen offers to buy out struggling neuro partner Sage Therapeutics

Gilead taps in­to STAT6 space via $250M deal with Leo Phar­ma

News Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Gilead taps into STAT6 space via $250M deal with Leo Pharma